Patents by Inventor Pasi Antero Janne

Pasi Antero Janne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING TREATMENTS
    Publication number: 20210017604
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: April 21, 2020
    Publication date: January 21, 2021
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred BELL, Daniel A. HABER, Pasi Antero JANNE, Bruce E. JOHNSON, Thomas J. LYNCH, Matthew MEYERSON, Juan Guillermo PAEZ, William R. SELLERS, Jeffrey E. SETTLEMAN, Raffaella SORDELLA
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 10669589
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: June 2, 2020
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING TREATMENTS
    Publication number: 20180251860
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 6, 2018
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred BELL, Daniel A. HABER, Pasi Antero JANNE, Bruce E. JOHNSON, Thomas J. LYNCH, Matthew MEYERSON, Juan Guillermo PAEZ, William R. SELLERS, Jeffrey E. SETTLEMAN, Raffaella SORDELLA
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 10000815
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: June 19, 2018
    Assignees: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING TREATMENTS
    Publication number: 20150176081
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: March 4, 2015
    Publication date: June 25, 2015
    Inventors: Daphne Winifred BELL, Daniel A. HABER, Pasi Antero JANNE, Bruce E. JOHNSON, Thomas J. LYNCH, Matthew MEYERSON, Juan Guillermo PAEZ, William R. SELLERS, Jeffrey E. SETTLEMAN, Raffaella SORDELLA
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 9035036
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: May 19, 2015
    Assignees: The General Hospital, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 8465916
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: June 18, 2013
    Assignees: The General Hospital Corporation, Dana Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnston, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 8105769
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: January 31, 2012
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnston, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 7964349
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: June 21, 2011
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnston, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Publication number: 20080234264
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: August 20, 2007
    Publication date: September 25, 2008
    Applicants: The General Hospital Corporation, Dana Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnston, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Publication number: 20080207615
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: August 20, 2007
    Publication date: August 28, 2008
    Applicants: The General Hospital Corporation, Dana Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnston, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 7294468
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: November 13, 2007
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella